Abstract: Slide Presentations |

To assess the clinical efficacy of azithromycin and capreomycin in the treatment of multi-drug resistant pulmonary tuberculosis FREE TO VIEW

Sudhir K. Agarwal, MD*
Author and Funding Information

Institute of Medical Sciences, Banaras Hindu University, Varanasi, India


Chest. 2004;126(4_MeetingAbstracts):752S. doi:10.1378/chest.126.4_MeetingAbstracts.752S-a
Text Size: A A A
Published online


PURPOSE:  The present study was done to see the clinical efficacy of azithromycin and capreomycin along with other anti-tuberculosis drugs in the treatment of MDR-TB.

METHODS:  Ninety-two patients (aged 18 years to 47 years) with MDR-TB were assigned to a study group (47 cases), treated with azithromycin, capreomycin, pyrazinamide (Z), ethambutol (E) and isoniazid (H); or a control group ( 45 cases), treated with streptomycin (S), ethambutol (E), Z and H. The course of treatment was 18 months. All patients were HIV negative, smear-positive, non-pregnant and had been receiving antituberculosis drugs for an average of 69 weeks (32 to 121 weeks). Sputum examination was done every 4 weeks.

RESULTS:  42 cases in the study group and 41 in the control group completed the treatment. The sputum negative conversion in the study group (82%) was significantly higher than in the control group (56%). The radiological improvement rate was 48% in the study group, significantly higher than that in the control group (28%) (P<0.01). The closure rate of the lung cavities in the study group (65%) was higher than in the control group (44%) (P<0.05). No significant difference was found in side-effects between the two groups.

CONCLUSION:  The regimen including azithromycin, capreomycin and other second-line anti-TB drugs was effective and safe for the patients with MDR-TB.

CLINICAL IMPLICATIONS:  Chemotherapy with capreomycin, azithromycin, pyrazinamide, ethambutol and isoniazid seems to be promising for Indian patients having MDR-TB.

DISCLOSURE:  S.K. Agarwal, None.

Tuesday, October 26, 2004

12:30 PM- 2:00 PM




Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
Antimycobacterial drugs. Semin Respir Infect 1994;9(2):84-103.
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543